$4.8 billion deal for gene therapy pioneer Spark Therapeutics delayed once more

The finish line for their proposed $4.8 billion deal is proving to be quite elusive for Roche and Spark Therapeutics. The companies announced Monday they have have each received a request for additional information and documentary material from the Federal Trade Commission in connection with the FTC's review of Roche’s pending acquisition of Spark (NASDAQ: ONCE), a Philadelphia gene therapy company. The reques t extends the waiting period for action on the proposed deal — part of the regulatory…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news